Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors
- Bioorg Med Chem Lett. 2019 Sep 15;29(18):2638-2645. doi: 10.1016/j.bmcl.2019.07.045.
- 1. Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
- 2. Department of Pharmacology, College of Basic Medicine, Qingdao University, Qingdao, Shandong, China.
- 3. Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
- 4. Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, Shandong, China. Electronic address: [email protected].
Histone deacetylases (HDACs) have proven to be promising targets for the development of anti-cancer drugs. In this study, we reported a series of novel chalcone based tubulin and HDAC dual-targeting inhibitors. Three compounds inhibited the activities of HDAC and tubulin polymerization simultaneously and displayed anti-proliferative activities toward eleven human tumor cell lines. Compound 8a remarkably induced growth inhibition, Apoptosis and G2/M phase arrest of A549 tumor cells. Finally, the inhibitory activities of 8a against HDAC6 and tubulin were rationalized by molecular docking studies.